Phase 2 HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You have been diagnosed with HIV-1
- Your CD4 cell count (a measure of immune system strength) is at least 200/mm³
- You have been on a stable HIV treatment regimen of at least 2 medications for at least 6 months
- Your HIV viral load (the amount of HIV in your blood) has stayed at or below 50 copies/mL for the past 12 months, with at most one small temporary rise (between 51–200 copies/mL) that returned back down (confirm with trial site)
- You have never taken the HIV medication doravirine before
- Your HIV virus does not show resistance (reduced response) to the medications doravirine or raltegravir, based on genetic testing of the virus
- You have signed a consent form agreeing to take part
- You are covered by a social health insurance programme (for patients in France, State Medical Aid/AME does not qualify)
Who may not be able to join:
- No genetic test results are available for your HIV virus, and a new test at the start of the trial also could not produce results (confirm with trial site)
- You also have hepatitis B (HBV) infection
- Your haemoglobin level (a measure of red blood cells) is below 9 g/dL
- Your platelet count (cells that help blood clot) is below 80,000/mm³
- Your kidneys are not filtering blood well enough (below a certain threshold on a standard kidney function test)
- Your liver enzyme levels (AST or ALT) are 5 times or more above the normal range
- You are currently taking antiviral medications to treat hepatitis C
- You have another serious illness at the same time
- You are taking any medication that could interact badly with doravirine
- You are currently taking interferon, interleukins, other immune-based therapies, or chemotherapy
- You are currently taking medication to prevent or treat an opportunistic infection (infections that occur when the immune system is weakened)
- You have habits or conditions — such as heavy alcohol or drug use — that the trial doctor believes could make it hard to follow the trial rules or tolerate the treatment
- You are under a form of legal protection due to reduced mental or physical capacity (this applies to French patients; confirm with trial site for equivalent situations in other countries)
- You are currently taking part in another clinical trial that has a rule preventing you from joining additional trials
- You are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christine Katlama, MD, Pitie-Salpetriere Hospital
Phone: 33142164181
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Measure the virological efficacy at week 48 of once daily doravirine plus raltegravir dual therapy to assess the effectiveness of the dual therapy DORAL to maintain the virological success to W48
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.